Nektar Therapeutics (NKTR)
Summary
NKTR Chart
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More
Nektar Therapeutics is downgraded from Strong Buy to Hold due to safety concerns with REZPEG despite positive efficacy data. Phase 2b REZOLVE-AA study showed 63% off-treatment durability but 91.7% injection site reactions, raising doubts about REZPEG's market potential in AA. NKTR maintains a strong cash position [$1.02B as of June 2026], sufficient to fund operations into Q3 2028, reducing near-term dilution risk.
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
Nektar Therapeutics NASDAQ: NKTR presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program.
3 Biotech Stocks Put Traders Are Targeting Today
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
Nektar Therapeutics (NKTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nektar Therapeutics ever had a stock split?
Nektar Therapeutics Profile
| Biotechnology Industry | Healthcare Sector | Howard W. Robin CEO | XMEX Exchange | US6402683063 ISIN |
| US Country | 63 Employees | - Last Dividend | 9 Jun 2025 Last Split | 3 May 1994 IPO Date |
Overview
Nektar Therapeutics is a prominent biopharmaceutical company specialized in the discovery and development of innovative therapies aimed at selectively modulating the immune system. With a primary focus on treating autoimmune disorders and chronic inflammatory conditions, Nektar Therapeutics leverages its expertise to create treatments that restore balance to the immune system. Operating both within the United States and internationally, the company's research and development efforts have led to the creation of a diverse pipeline of therapeutic candidates. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California, and maintains collaborative agreements with a range of leading pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, and Pfizer Inc., among others. This extensive network of collaborations underlines the company's commitment to advancing healthcare through innovation.
Products and Services
- NKTR-358: A pioneering therapeutic asset aimed at stimulating regulatory T (Treg) cells. This treatment is designed to correct the immune imbalance that underlies autoimmune diseases and chronic inflammatory conditions, representing a novel approach in the management of these disorders.
- PEG-CSF1: An engineered polyethylene glycol (PEG) modified hematopoietic colony-stimulating factor protein. PEG-CSF1 selectively modulates inflammation resolution processes and has broad applications across various therapeutic indications, including both acute and chronic inflammation. This versatility underscores its potential in addressing multiple health conditions.
- Tumor Necrosis Factor (TNF) Receptor Type II (TNFR2) Agonist Asset: A bivalent antibody molecule designed to selectively stimulate TNFR2 receptor activity. This asset avoids modulation of TNFR1 signaling, offering a targeted approach to stimulating the immune response in a way that could benefit patients with certain conditions.
- NKTR-255: An IL-15 receptor agonist that aims to enhance the body's natural cancer-fighting abilities. By boosting the immune system, NKTR-255 represents a promising tool in the fight against cancer, adding to the company's diverse portfolio of innovative therapies.
Contact Information
